Ultrasound-Responsive Liposomes for Targeted Drug Delivery Combined with Focused Ultrasound

• Published in: Pharmaceutics Vol. 14; no. 7; p. 1314
• Main Authors: Kim, Yoon-Seok, Ko, Min Jung, Moon, Hyungwon, Sim, Wonchul, Cho, Ae Shin, Gil, Gio, Kim, Hyun Ryoung
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 21-06-2022; MDPI
• Subjects: Biodistribution; Blood vessels; Cancer therapies; Chemotherapy; Cholesterol; Drugs; Ethanol; high-intensity focused ultrasound; Lipids; liposomal doxorubicin; Permeability; Pharmacokinetics; stimuli-triggered drug release; triple-negative breast cancer; Tumors; Ultrasonic imaging; ultrasound-responsive liposome; United States > US
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics14071314

Chemotherapeutic drugs are traditionally used for the treatment of cancer. However, chemodrugs generally induce side effects and decrease anticancer effects due to indiscriminate diffusion and poor drug delivery. To overcome these limitations of chemotherapy, in this study, ultrasound-responsive liposomes were fabricated and used as drug carriers for delivering the anticancer drug doxorubicin, which was able to induce cancer cell death. The ultrasound-sensitive liposome demonstrated a size distribution of 81.94 nm, and the entrapment efficiency of doxorubicin was 97.1 ± 1.44%. The release of doxorubicin under the ultrasound irradiation was 60% on continuous wave and 50% by optimizing the focused ultrasound conditions. In vivo fluorescence live imaging was used to visualize the doxorubicin release in the MDA-MB-231 xenografted mouse, and it was demonstrated that liposomal drugs were released in response to ultrasound irradiation of the tissue. The combination of ultrasound and liposomes suppressed tumor growth over 56% more than liposomes without ultrasound exposure and 98% more than the control group. In conclusion, this study provides a potential alternative for overcoming the previous limitations of chemotherapeutics.